Prognostic Value of Hematologic Parameters in Patients with Metastatic Renal Cell Carcinoma Using Tyrosine Kinase Inhibitors |
Gunduz, Seyda
(Department of Medical Oncology, Faculty of Medicine, Akdeniz University Antalya)
Mutlu, Hasan (Department of Medical Oncology, Faculty of Medicine, Akdeniz University Antalya) Uysal, Mukremin (Department of Medical Oncology, Ahmet Necdet Sezer Research and Practice Hospital, Afyon Kocatepe University) Coskun, Hasan Senol (Department of Medical Oncology, Faculty of Medicine, Akdeniz University Antalya) Bozcuk, Hakan (Department of Medical Oncology, Faculty of Medicine, Akdeniz University Antalya) |
1 | Heng DY, Xie W, Regan MM, et al (2009). Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factortargeted agents: results from a large, multicenter study. J Clin Oncol, 27, 5794-9. DOI ScienceOn |
2 | Kapoor AK, Hotte SJ (2007). Current status of cytokine therapy in management of patients with metastatic renal cell carcinoma. Can Urol Assoc J, 1, 28-33. |
3 | Mathew A, Devesa SS, Fraumeni JF, et al (2002). Global increases in kidney cancer incidence, 1973-1992. Eur J Cancer Prev, 11, 171-8. DOI ScienceOn |
4 | Zheng YB, Zhao W, Liu B, et al (2013). The blood neutrophil-tolymphocyte ratio predicts survival in patients with advanced hepatocellular carcinoma receiving sorafenib. Asian Pac J Cancer Prev, 14, 5527-31. 과학기술학회마을 DOI ScienceOn |
5 | Yang JC, Sherry RM, Steinberg SM, et al (2003). Randomized study of high-dose and low-dose interleukin-2 in patients withmetastatic renal cancer. J Clin Oncol, 21, 3127-32. DOI ScienceOn |
6 | Motzer RJ, Michaelson MD, Redman BG, et al (2006). Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol, 24, 16-24. DOI ScienceOn |
7 | Willett CG, Boucher Y, di Tomaso E, et al (2004). Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med, 10, 145. DOI ScienceOn |
8 | Ohno Y, Nakashima J, Ohori M, et al (2010). Pretreatment neutrophil-to-lymphocyte ratio as an independent predictor of recurrence in patients with nonmetastatic renal cell carcinoma. J Urol, 184, 873-8. DOI ScienceOn |
9 | Motzer RJ, Hutson TE, Tomczak P, et al (2007). Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med, 356, 115-24. DOI ScienceOn |
10 | Motzer RJ, Hutson TE, Olsen MR, et al (2011). Randomized phase II multicenter study of the efficacy and safety of sunitinib on the 4/2 versus continupus dosing schedule as first-line therapy of metastatic renal cell carcinoma: renal EFFECT trial. J Clin Oncol, 29, 308. DOI |
11 | Ohno Y, Nakashima J, Ohori M, et al (2012). Followup of neutrophil-to-lymphocyte ratio and recurrence of clear cell renal cell carcinoma. J Urol, 187, 411-7. DOI ScienceOn |
12 | Porta C, Procopio G, Carteni G, et al (2011). Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases. BJU Int, 108, 250-7. DOI ScienceOn |
13 | Sternberg CN, Davis ID, Mardiak J, et al (2010). Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol, 28, 1061-8. DOI ScienceOn |
14 | AJCC Cancer Staging Manual, Seventh Edition (2010). published by Springer New York, Inc. |
15 | Unal D, Eroglu C, Kurtul N, Oguz A, Tasdemir A (2013). Are neutrophil/lymphocyte and platelet/lymphocyte rates in patients with non-small cell lung cancer associated with treatment response and prognosis? Asian Pac J Cancer Prev, 14, 5237-42. 과학기술학회마을 DOI ScienceOn |
16 | Dirican A, Kucukzeybek Y, Erten C, et al (2013). Prognostic and predictive value of hematologic parameters in patients with metastatic renal cell carcinoma: second line sunitinib treatment following IFN-alpha. Asian Pac J Cancer Prev, 14, 2101-5. 과학기술학회마을 DOI ScienceOn |
17 | Al-Marrawi MY, Rini BI, Harshman GA, et al (2011). The association of clinical outcome to front-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma (mRCC) patients (Pts.). J Clin Oncol, 29, 4555. DOI |
18 | Cohen RB, Oudard S (2012). Antiangiogenic therapy for advanced renal cell carcinoma: management of treatmentrelated toxicities. Invest New Drugs, 30, 2066-79. DOI |
19 | Donskov F (2013). Immunomonitoring and prognostic relevance of neutrophils in clinical trials. Sem Cancer Biol, 23, 200-7. DOI ScienceOn |
20 | Ferlay J, Shin HR, Bray F, et al (2010) International Agency for Research on Cancer. The GLOBOCON Project. http://globocan.iarc.fr. |
21 | Hanninen LE, Kirchner H, Atzpodien J (1996). Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients. J Urol, 155, 19-25. DOI ScienceOn |
![]() |